Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;333:46 (1 July), doi:10.1136/bmj.333.7557.46
| The first 150 words of the full text of this article appear below. |
EDITORManuel et al show that guidelines on statin treatment should focus on people with the highest risk of coronary heart disease.1 However, concerns about the optimal choice of statins remain.
A recent meta-analysis (n = 71 108) of randomised controlled trials has shown that the occurrence of myalgia is less common with fluvastatin, pravastatin, and simvastatin than atorvastatin (odds ratio 0.28, 95% confidence interval 0.18 to 0.44; 0.43, 0.36 to 0.51; 0.23, 0.19 to 0.28; respectively).2 This observation could also be supported by Japanese postmarketing surveys for both atorvastatin and pitavastatin.3 4 For example, atorvastatin had an increased risk of musculoskeletal adverse events including the elevations of serum creatine phosphokinase as an important indicator of rhabdomyolysis compared with pitavastatin in Japanese common clinical practice (atorvastatin 144/4805, pitavastatin 154/7930; risk ratio 1.54, confidence interval 1.23 to 1.93; P = 0.0001 by using the Mann-Whitney U test).3 4 This difference was shown
Hisashi Moriguchi, professor
Laboratory for Systems Biology and Medicine, RCAST, University of Tokyo, 4-6-1, Komaba, Meguro-ku, Tokyo, Japan 153-8904 moriguchi@lsbm.org
Takamoto Uemura, assistant professor
Kyorin University, Tokyo
Chifumi Sato, professor
Tokyo Medical and Dental University, Tokyo